Oculis Holding AG (OCS) NASDAQ
12.60
-1.91(-13.16%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Oculis Holding AG
Sector
Healthcare
Industry
Biotechnology
Employees
49
First IPO Date
May 18, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Riad Sherif | Chief Executive Officer & Director | 0 | 1968 |
| Ramin Tadayoni | Chief Scientific Officer | 0 | N/A |
| Snehal Shah | President of Research & Development | 0 | N/A |
| Páll Ragnar Jóhannesson | Chief Business Officer | 0 | 1982 |
| Rebecca Weil | Chief Commercial Officer | 0 | N/A |
| Sylvia Cheung | Chief Financial Officer | 0 | 1975 |
| Virginia R. Dean | Chief Human Resources Officer | 0 | 1966 |
| Gudrun Bachmann | Chief Technology Officer | 0 | N/A |
| Katie Kazem | Chief Legal Officer | 0 | N/A |
| Sharon Klier | Chief Development Officer | 0 | N/A |
Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
